Programmed death-ligand 1 expression and prognostic significance in bevacizumab treated ovarian cancer patients: Results from the phase IV MITO16A/MaNGO OV-2 translational study

Francesca Basso-Valentina; Vincenzo Canzonieri; Rossella De Cecio; Laura Arenare; Domenica Lorusso; Sabrina Chiara Cecere; Eliana Pivetta; Daniela Russo; Annabella Di Mauro; Grazia Artioli; Anna Spina; Carmine De Angelis; Daniela Califano; Saverio Cinieri; Giosuè Scognamiglio; Vanda Salutari; Paolo Chiodini; Francesco Perrone; Sandro Pignata; Gustavo Baldassarre

doi:10.1002/ctm2.70373

Clinical and Translational Medicine ›› 2025, Vol. 15 ›› Issue (6) : e70373 DOI: 10.1002/ctm2.70373

LETTER TO THE JOURNAL

Programmed death-ligand 1 expression and prognostic significance in bevacizumab treated ovarian cancer patients: Results from the phase IV MITO16A/MaNGO OV-2 translational study

Author information +

¹. Molecular Oncology Unit, Department of Research and Diagnostic, Centro di Riferimento Oncologico di Aviano (CRO), IRCCS, National Cancer Institute, Aviano, Italy

². Pathology Unit, Department of Research and Diagnostic, Centro di Riferimento Oncologico di Aviano (CRO), IRCCS, National Cancer Institute, Aviano, Italy

³. Department of Medical, Surgical and Health Sciences, University of Trieste, Trieste, Italy

⁴. Pathology Unit, Istituto Nazionale Tumori IRCCS - Fondazione G. Pascale, Naples, Italy

⁵. Clinical Trials Unit, Istituto Nazionale Tumori IRCCS - Fondazione G. Pascale, Naples, Italy

⁶. Department of Life Science and Public Health, Catholic University of Sacred Heart Largo Agostino Gemelli and Fondazione Policlinico Universitario A. Gemelli, IRCCS, Rome, Italy

⁷. Uro-Gynecological Medical Oncology, Istituto Nazionale Tumori IRCCS - Fondazione G. Pascale, Naples, Italy

⁸. Microenvironment Molecular Targets Unit, Istituto Nazionale Tumori IRCCS - Fondazione G. Pascale, Naples, Italy

⁹. Oncologia Medica, ULSS 2 Marca Trevigiana, Treviso, Italy

¹⁰. Department of Medical Oncology, School of Medicine and Surgery, University of Naples Federico II, Naples, Italy

¹¹. Medical Oncology Division and Breast Unit, Senatore Antonio Perrino Hospital, ASL Brindisi, Brindisi, Italy

¹². Scientific Directorate, Istituto Nazionale Tumori IRCCS - Fondazione G. Pascale, Naples, Italy

¹³. Department of Mental Health and Public Medicine, Section of Statistics, Università degli Studi della Campania Luigi Vanvitelli, Naples, Italy

s.pignata@istitutotumouri.na.it

gbaldassarre@cro.it

Show less

History +

PDF

Cite this article

Download citation ▾

Francesca Basso-Valentina, Vincenzo Canzonieri, Rossella De Cecio, Laura Arenare, Domenica Lorusso, Sabrina Chiara Cecere, Eliana Pivetta, Daniela Russo, Annabella Di Mauro, Grazia Artioli, Anna Spina, Carmine De Angelis, Daniela Califano, Saverio Cinieri, Giosuè Scognamiglio, Vanda Salutari, Paolo Chiodini, Francesco Perrone, Sandro Pignata, Gustavo Baldassarre. Programmed death-ligand 1 expression and prognostic significance in bevacizumab treated ovarian cancer patients: Results from the phase IV MITO16A/MaNGO OV-2 translational study. Clinical and Translational Medicine, 2025, 15(6): e70373 DOI:10.1002/ctm2.70373

登录浏览全文

4963

注册一个新账户忘记密码

References

Publishing order | Descend order by publishing year | Descend order by cited within

[1]	Bagchi S, Yuan R, Engleman EG. Immune checkpoint inhibitors for the treatment of cancer: clinical impact and mechanisms of response and resistance. Ann Rev Pathol: Mech Dis. 2021; 16: 223-249.

[2]	Peng Z, Li M, Li H, Gao Q. PD-1/PD-L1 immune checkpoint blockade in ovarian cancer: dilemmas and opportunities. Drug Discov Today. 2023; 28: 103666.

[3]	Ghisoni E, Imbimbo M, Zimmermann S, Valabrega G. Ovarian cancer immunotherapy: turning up the Heat. Int J Mol Sci. 2019; 20: 2927.

[4]	Moore KN, Bookman M, Sehouli J, et al. Atezolizumab, bevacizumab, and chemotherapy for newly diagnosed stage III or IV ovarian cancer: placebo-controlled randomized phase III trial (IMagyn050/GOG 3015/ENGOT-OV39). J Clin Oncol.2021; 39: 1842-1855.

[5]	Freyer G, Floquet A, Tredan O, et al. Bevacizumab, olaparib, and durvalumab in patients with relapsed ovarian cancer: a phase II clinical trial from the GINECO group. Nat Commun. 2024; 15: 1985.

[6]	Banerjee S, Ghisoni E, Wolfer A, et al. Bevacizumab, atezolizumab and acetylsalicylic acid in recurrent, platinum-resistant ovarian cancer: the EORTC 1508-GCG phase II study. Clin Cancer Res. 2025; 31: 2145-2153.

[7]	Daniele G, Raspagliesi F, Scambia G, et al. Bevacizumab, carboplatin, and paclitaxel in the first line treatment of advanced ovarian cancer patients: the phase IV MITO-16A/MaNGO-OV2A study. Int J Gynecol Cancer. 2021; 31: 875-882.

[8]	Parra ER, Villalobos P, Mino B, Rodriguez-Canales J. Comparison of different antibody clones for immunohistochemistry detection of programmed cell death ligand 1 (PD-L1) on non-small cell lung carcinoma. Appl Immunohistochem Mol Morphol. 2018; 26: 83.

[9]	Morse CB, Toukatly MN, Kilgore MR, et al. Tumor infiltrating lymphocytes and homologous recombination deficiency are independently associated with improved survival in ovarian carcinoma. Gynecol Oncol. 2019; 153: 217-222.

[10]	Holländer N, Sauerbrei W, Schumacher M. Confidence intervals for the effect of a prognostic factor after selection of an “optimal” cutpoint. Stat Med. 2004; 23: 1701-1713.

RIGHTS & PERMISSIONS

2025 The Author(s). Clinical and Translational Medicine published by John Wiley & Sons Australia, Ltd on behalf of Shanghai Institute of Clinical Bioinformatics.